Attovia Therapeutics, Inc. - Common Stock (ATTO)

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with chronic pruritus of unknown origin and in those with high-itch atopic dermatitis. The company plan

Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD)

SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:

ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026

SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the closing of its upsized initial public offering of 19,550,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,550,000 additional shares, at the initial public offering price of $17.00 per share. The aggregate gross proceeds to Attovia from the initial public offering were approximately $332.4 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares were offered by Attovia. Attovia’s common stock began trading on the Nasdaq Global Market on August 5, 2026, under the symbol “ATTO.”